The Latest Cardiac and Vascular News
IRVINE, Calif., Jan. 30, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2019. Fourth Quarter Results and Outlook Q4 sales grew 20% to $1.2 billion; underlying1 sales grew 19% Q4 TAVR sales grew […]
NEW YORK, Dec. 5, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance during its annual investor conference today in New […]
IRVINE, Calif., Oct. 23, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended September 30, 2019. Third Quarter and Recent Highlights Sales grew 21% to $1.1 billion; underlying1 sales grew 19% TAVR sales grew 26%; […]
SAN JOSÉ, Costa Rica, Oct. 10, 2019 /PRNewswire/ — Edwards Lifesciences Corporation, a world leader in innovations for structural heart disease and critical care monitoring aimed at patients, expanded its presence in Costa Rica with a $100 million investment and the addition of 500 new jobs by the end of 2020. The brand new facility is located […]
SAN FRANCISCO, Sept. 29, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced new data demonstrating early and sustained health status advantages for severe aortic stenosis (AS) patients at low surgical risk treated with the Edwards SAPIEN 3 valve. […]
IRVINE, Calif., July 23, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2019. Second Quarter and Recent Highlights Sales grew 15% to $1.1 billion; underlying1 sales grew 14% TAVR sales grew 16%; underlying […]
IRVINE, Calif., June 3, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited “mini-tender offer” by TRC Capital Corporation to purchase up to 1,000,000 shares, or approximately 0.48 percent of the […]
PARIS, May 22, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced strategic clinical and regulatory milestones for its Edwards PASCAL transcatheter valve repair system. Today at the EuroPCR annual course in Paris, new 6-month data from the CLASP study of […]
IRVINE, Calif., March 11, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in an exclusive right to acquire Corvia Medical, Inc., the developer of […]
